Comments
Three studies back Sanofi's Lantus safety
12.06.2012. | PARIS (Reuters) - French drugmaker Sanofi's top-selling insulin Lantus does not increase the risk of cancer, three large-scale studies in Europe and the United States found, after previous suggestions there may be a link....
